At least 1 dose of BMS-791325 can be identified which is safe, well tolerated, and
efficacious when combined with peg-interferon alfa-2a (pegIFNα-2a)/ribavirin (RBV) for the
treatment of treatment-naïve, chronically-infected hepatitis C virus (HCV) genotype 1
subjects